Literature DB >> 9502595

Evaluation of recombinant dengue viral envelope B domain protein antigens for the detection of dengue complex-specific antibodies.

M Simmons1, K R Porter, J Escamilla, R Graham, D M Watts, K H Eckels, C G Hayes.   

Abstract

To increase the specificity of dengue (DEN) diagnosis based on antibody detection, we have evaluated recombinant proteins as antigens that incorporate most of the B domain of the DEN virus envelope protein fused to the trpE protein of Escherichia coli (trpE-DEN). A pooled antigen consisting of trpE-DEN proteins representing all four serotypes of DEN virus was used in an indirect ELISA for the detection of IgG or IgM antibody. This assay was compared with a standard IgG indirect ELISA and an IgM-capture ELISA using DEN virus-infected cell culture pooled antigens. The results indicated that the trpE-DEN antigens and the cell culture antigens were equally sensitive for detecting IgM and IgG antibodies in convalescent sera from Peru and Indonesia representing virus isolation-confirmed primary and secondary DEN infections, respectively. Fourteen day postinfection IgG antibody-positive sera obtained from individuals infected with DEN-1 virus who had been vaccinated with other flaviviruses were more strongly reactive with the cell culture antigen than with the recombinant antigen, but by day 21 postinfection, a strong antibody response to the trpE-DEN antigens was present. These results suggested that the early antibody response was directed predominantly towards shared flavivirus group antigens that were not detected with the trpE-DEN antigens. Comparison of the trpE-DEN-1 recombinant antigen with a DEN-1 virus-infected cell lysate antigen for the detection of IgG antibody in sera from a cohort of 55 individuals from Peru who seroconverted over a one-year period indicated greater specificity for the recombinant antigens. Also, sera from individuals with no known DEN infections that had been sequentially vaccinated with yellow fever and Japanese encephalitis reacted with the DEN virus cell culture antigen in the IgG ELISA, but did not react with the trpE-DEN pooled antigens. Similarly, YF IgM antibody positive samples that showed cross-reactivity with the DEN virus cell culture antigens, did not react with the trpE-DEN pooled antigens. These results indicated that the trpE-DEN pooled antigen provided a more specific diagnosis of dengue infections than DEN virus-infected cell culture antigen and avoided the biohazards associated with handling live virus during the preparation of diagnostic reagents. The trpE-DEN pooled antigen should permit a better approach to distinguish between past DEN and other flavivirus infections in epidemiologic surveys, and also increase the specificity of serologic diagnosis of acute DEN infections.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9502595     DOI: 10.4269/ajtmh.1998.58.144

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

1.  Serological differentiation of infections with dengue virus serotypes 1 to 4 by using recombinant antigens.

Authors:  Diana Ludolfs; Stefan Schilling; Jan Altenschmidt; Herbert Schmitz
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein.

Authors:  John T Roehrig; Katharine E Volpe; Jennifer Squires; Ann R Hunt; Brent S Davis; Gwong-Jen J Chang
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Immunoglobulin M enzyme-linked immunosorbent assay using recombinant polypeptides for diagnosis of dengue.

Authors:  Elsa Videa; Maria Josefina Coloma; Flavia Barreto Dos Santos; Angel Balmaseda; Eva Harris
Journal:  Clin Diagn Lab Immunol       Date:  2005-07

4.  Single antigen detects both immunoglobulin M (IgM) and IgG antibodies elicited by all four dengue virus serotypes.

Authors:  Menaka D Hapugoda; Gaurav Batra; W Abeyewickreme; S Swaminathan; N Khanna
Journal:  Clin Vaccine Immunol       Date:  2007-09-26

5.  Use of a recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile virus infection.

Authors:  David W C Beasley; Michael R Holbrook; Amelia P A Travassos Da Rosa; Lark Coffey; Anne-Sophie Carrara; Kathrine Phillippi-Falkenstein; Rudolf P Bohm; Marion S Ratterree; Kristy M Lillibridge; George V Ludwig; Jose Estrada-Franco; Scott C Weaver; Robert B Tesh; Robert E Shope; Alan D T Barrett
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

6.  Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera.

Authors:  Gaurav Batra; Satish K Nemani; Poornima Tyagi; Sathyamangalam Swaminathan; Navin Khanna
Journal:  BMC Infect Dis       Date:  2011-03-15       Impact factor: 3.090

7.  The tetravalent formulation of domain III-capsid proteins recalls memory B- and T-cell responses induced in monkeys by an experimental dengue virus infection.

Authors:  Lázaro Gil; Laura Lazo; Iris Valdés; Edith Suzarte; Phuong Yen; Rosa Ramírez; Mayling Álvarez; Le T Dung; Karem Cobas; Ernesto Marcos; Yusleidi Pérez; María G Guzmán; Ngyen D Hien; Gerardo Guillén; Lisset Hermida
Journal:  Clin Transl Immunology       Date:  2017-06-23

8.  Reverse ELISA for the detection of anti West Nile virus IgG antibodies in humans.

Authors:  D Ludolfs; M Niedrig; J T Paweska; H Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07       Impact factor: 5.103

9.  Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins.

Authors:  Nora Zidane; Philippe Dussart; Laetitia Bremand; Hugues Bedouelle
Journal:  BMC Infect Dis       Date:  2013-07-01       Impact factor: 3.090

10.  Casamino acids facilitate the secretion of recombinant dengue virus serotype-3 envelope domain III in Pichia pastoris.

Authors:  Neha Kaushik; Deepak Rohila; Upasana Arora; Rajendra Raut; Urpo Lamminmäki; Navin Khanna; Gaurav Batra
Journal:  BMC Biotechnol       Date:  2016-02-04       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.